Physician profile

David J Koster

Hematology & Oncology · Fresno, CA

NPI 1063406163

$459.61

in general payments reported to CMS, 2019-2025

17 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$15.14

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Biotech, INC. $69.42 2019-2020
Astrazeneca Pharmaceuticals LP $55.28 2019
Amgen INC. $45.21 2019-2022
E.R. Squibb & Sons, L.L.C. $40.97 2019
Novartis Pharmaceuticals Corporation $34.32 2019-2021
Merck Sharp & Dohme LLC $30.51 2019
Morphosys, US INC. $25.00 2022
Tesaro, INC. $24.27 2019
Emd Serono, INC. $23.47 2022
Takeda Pharmaceuticals U.S.A., INC. $16.33 2019
Pfizer INC. $16.08 2019
Celgene Corporation $15.14 2023
Lilly USA, LLC $15.13 2019
Seqirus USA INC $13.73 2022
Gilead Sciences, INC. $11.92 2021
Show all 17 companies
CompanyGeneral paymentsYearsTop products
Masimo Corporation $11.60 2020
Regeneron Healthcare Solutions, INC. $11.23 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David J Koster

$459.61

in general payments reported 2019-2025

Years
2019-2023
Top company
Janssen Biotech, INC.

https://glasscript.com/doctor/228815/david-j-koster

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.